| - | Human, | AD, | NA |
| 3827- | Aroma, | A medicinal herb, Melissa officinalis L. ameliorates depressive-like behavior of rats in the forced swimming test via regulating the serotonergic neurotransmitter |
| - | in-vivo, | NA, | NA |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 3384- | ART/DHA, | Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Liver, | HepG2 |
| 3385- | ART/DHA, | Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study |
| - | Study, | NA, | NA |
| 3386- | ART/DHA, | Effects of Caffeine-Artemisinin Combination on Liver Function and Oxidative Stress in Selected Organs in 7,12-Dimethylbenzanthracene-Treated Rats |
| - | in-vivo, | Nor, | NA |
| 3387- | ART/DHA, | Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment |
| - | Review, | Var, | NA |
| 3388- | ART/DHA, | Keap1 Cystenine 151 as a Potential Target for Artemisitene-Induced Nrf2 Activation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 | - | in-vitro, | BC, | MDA-MB-231 |
| 3389- | ART/DHA, | Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers |
| - | Review, | Var, | NA |
| 3390- | ART/DHA, | Ferroptosis: The Silver Lining of Cancer Therapy |
| 3345- | ART/DHA, | Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells |
| - | in-vitro, | GBM, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 3392- | ART/DHA, | Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways |
| - | in-vitro, | Nor, | Hep3B | - | in-vivo, | NA, | NA |
| 3393- | ART/DHA, | Artemisinin-derived artemisitene blocks ROS-mediated NLRP3 inflammasome and alleviates ulcerative colitis |
| - | in-vivo, | Col, | NA |
| 3394- | ART/DHA, | Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine |
| 3395- | ART/DHA, | Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis |
| - | in-vitro, | NA, | HSC-T6 |
| 3396- | ART/DHA, | Progress on the study of the anticancer effects of artesunate |
| - | Review, | Var, | NA |
| 3665- | ART/DHA, | Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation |
| - | Review, | AD, | NA |
| 3666- | ART/DHA, | Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling |
| - | NA, | AD, | NA |
| 3667- | ART/DHA, | Artemisinin improves neurocognitive deficits associated with sepsis by activating the AMPK axis in microglia |
| - | Review, | Sepsis, | NA |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| - | in-vitro, | AML, | THP1 |
| 5381- | ART/DHA, | Artemisitene triggers calcium-dependent ferroptosis by disrupting the LSH-EWSR1 interaction in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT8 |
| 5383- | ART/DHA, | Artesunate is a drug used to treat severe malaria. |
| - | Review, | Var, | NA |
| 5382- | ART/DHA, | A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies |
| - | Trial, | Var, | NA |
| 5380- | ART/DHA, | Artemisinin and Its Derivatives as Potential Anticancer Agents |
| - | Review, | Var, | NA |
| 5379- | ART/DHA, | Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance—from immune microenvironment crosstalk to therapeutic translation |
| 5378- | ART/DHA, | Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives |
| - | Review, | Var, | NA |
| 5377- | ART/DHA, | Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein |
| - | in-vitro, | AML, | NA |
| 5376- | ART/DHA, | Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW48 | - | in-vitro, | BC, | MDA-MB-453 |
| 4278- | ART/DHA, | Artemisinin Ameliorates the Neurotoxic Effect of 3-Nitropropionic Acid: A Possible Involvement of the ERK/BDNF/Nrf2/HO-1 Signaling Pathway |
| - | in-vivo, | NA, | NA |
| 5129- | ART/DHA, | Evidence for the Involvement of Carbon-centered Radicals in the Induction of Apoptotic Cell Death by Artemisinin Compounds |
| - | in-vitro, | AML, | HL-60 |
| 5137- | ART/DHA, | Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin |
| - | vitro+vivo, | ESCC, | Eca109 |
| 5136- | ART/DHA, | Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis |
| - | in-vitro, | Var, | NA |
| 5135- | ART/DHA, | Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells |
| - | vitro+vivo, | Var, | NA |
| 5134- | ART/DHA, | Dihydroartemisinin induces autophagy by suppressing NF-κB activation |
| - | in-vitro, | Var, | NA |
| 5133- | ART/DHA, | Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 5132- | ART/DHA, | Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 5131- | ART/DHA, | Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells |
| - | in-vitro, | NSCLC, | ASTC-a-1 |
| 5130- | ART/DHA, | Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 4991- | ART/DHA, | doxoR, | Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy |
| - | in-vivo, | Nor, | H9c2 |
| 4992- | ART/DHA, | Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway |
| - | in-vitro, | AML, | HL-60 |
| 4993- | ART/DHA, | Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway |
| - | vitro+vivo, | GC, | NA |
| 573- | ART/DHA, | Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model |
| - | vitro+vivo, | NA, | NA |
| 576- | ART/DHA, | Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome |
| - | Analysis, | NA, | NA |
| 575- | ART/DHA, | Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition |
| - | in-vitro, | GBM, | U87MG |
| 574- | ART/DHA, | Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway |
| 572- | ART/DHA, | High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: Involvement of mitochondrial metabolism |
| 571- | ART/DHA, | TMZ, | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| - | vitro+vivo, | GBM, | A172 | - | vitro+vivo, | GBM, | U87MG |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid